Jupiter Neurosciences Inc

JUNS

0.599USD

-0.016-2.65%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Jupiter Neurosciences Inc's Score

Industry at a Glance

Industry Ranking

131 / 392

Overall Ranking

269 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Jupiter Neurosciences Inc Highlights

StrengthsRisks

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

Overvalued

The company’s latest PE is -2.57, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.39M shares, increasing 42.13% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 248.93K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

25.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Jupiter Neurosciences Inc is 6.96, ranking 178 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.96

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Jupiter Neurosciences Inc is 6.45, ranking 277 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.57, which is -11.94% below the recent high of -2.26 and -12960.79% above the recent low of -335.30.

Score

Industry at a Glance

Previous score

6.45

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 131/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Jupiter Neurosciences Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Jupiter Neurosciences Inc is 6.93, ranking 136 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.97 and the support level at 0.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.00

Change

-0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Rosen (Christer)

11.08M

--

Wahlestedt (Claes M.D., Ph.D.)

2.80M

-6.29%

Hayward (Marshall A Ph.D.)

2.38M

--

Brothers (Shaun P.)

1.70M

+12.46%

Vestor Capital Partners, LLC

970.99K

--

Rosen (Alexander Gustaf Erik)

452.86K

--

The Vanguard Group, Inc.

Star Investors

215.83K

--

Silva (Alison D)

112.78K

--

Geode Capital Management, L.L.C.

103.81K

+554.57%

Elmasri (Saleem C)

66.29K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Jupiter Neurosciences Inc is 2.36, ranking 233 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Jupiter Neurosciences Inc

JUNS

6.23 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment